The DOI matches its Crossref record, with a small difference in title or year; 59 of the 60 references it cites were found in a registry or an index.
A novel gene containing a trinucleotide repeat that is expanded and unstable on Huntington's disease chromosomes
Open accessAbstract
The Huntington's disease (HD) gene has been mapped in 4p16.3 but has eluded identification. We have used haplotype analysis of linkage disequilibrium to spotlight a small segment of 4p16.3 as the likely location of the defect. A new gene, IT15, isolated using cloned trapped exons from the target area contains a polymorphic trinucleotide repeat that is expanded and unstable on HD chromosomes. A (CAG)n repeat longer than the normal range was observed on HD chromosomes from all 75 disease families examined, comprising a variety of ethnic backgrounds and 4p16.3 haplotypes. The (CAG)n repeat appears to be located within the coding sequence of a predicted approximately 348 kd protein that is widely expressed but unrelated to any known gene. Thus, the HD mutation involves an unstable DNA segment, similar to those described in fragile X syndrome, spino-bulbar muscular atrophy, and myotonic dystrophy, acting in the context of a novel 4p16.3 gene to produce a dominant phenotype.
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
The source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“Huntington’s Disease arises from an expansion of cytosine-adenine-guanine (CAG) trinucleotide repeats in the HTT gene (formerly IT15) of chromosome 4p16.3, leading to the production of a dysfunctional huntingtin protein (polyQ-HTT) [161,162].”
From The Impact of Neurotoxin Proteins Trafficked by Primary Cilia and Extracellular Vesicles in Neurodegenerative Diseases (2025) · cites this paper as [162]
Experimental — accuracy not yet measuredThe source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“HD is usually confirmed diagnostically through the identification of 36 or more CAG repeats on the short arm of chromosome 4p16.3 in the Huntingtin gene [162].”
From The Impact of Neurotoxin Proteins Trafficked by Primary Cilia and Extracellular Vesicles in Neurodegenerative Diseases (2025) · cites this paper as [162]
Experimental — accuracy not yet measuredThe source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“HD etiology is entirely due to autosomal-dominant HTT mutations with abnormal CAG repeat expansion in exon 1, producing mutant huntingtin protein that aggregates and leads to neurodegeneration (379).”
From Blood-Brain Barrier: From Physiology to Disease and Back (2019) · cites this paper as [379]
Experimental — accuracy not yet measuredThe source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“Huntington’s disease (HD) is an inherited disorder caused by a CAG trinucleotide repeat expansion in HTT which leads to progressive motor and cognitive impairment due to the gradual loss of neurons within striatal and cortical brain regions [1].”
From miR-10b-5p expression in Huntington’s disease brain relates to age of onset and the extent of striatal involvement (2015) · cites this paper as [1]
Experimental — accuracy not yet measuredIn the citing paper
“The cause of Huntington's disease, an autosomal dominant neurological disorder, is well established as an abnormal expansion of CAG triplet repeats in exon 1 of the ubiquitously expressed huntingtin ( HTT ) gene, resulting in an elongated polyglutamine (Q) tract in the mutant huntingtin protein (mHTT) (MacDonald et al. , 1993).”
From Microglial depletion prevents extracellular matrix changes and striatal volume reduction in a model of Huntington's disease (2020) · cites this paper as MacDonald et al., 1993
In the citing paper
“In Huntington disease, poly-glutamine-expanded mHTT aggregates and accumulates194”
From PROTAC targeted protein degraders: the past is prologue (2022) · cites this paper as [194]
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Basic local alignment search tool
Altschul, S. F., Gish, W., Miller, W., Myers, E. W., & Lipman, D. J. (1990) · Journal of Molecular Biology · doi:10.1006/jmbi.1990.9999 · Cited by 98,669
DNA sequencing with chain-terminating inhibitors
Sanger, F., Nicklen, S., & Coulson, A. R. (1977) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.74.12.5463 · Cited by 68,572
Verkerk, A. J. M. H., Pieretti, M., Sutcliffe, J. S., Fu, Y.-H., Kuhl, D. P. A., Pizzuti, A., Reiner, O., Richards, S., Victoria, M. F., Zhang, F., et al. (1991) · Cell · doi:10.1016/0092-8674(91)90397-h · Cited by 3,481
Androgen receptor gene mutations in X-linked spinal and bulbar muscular atrophy
Spada, A. L., Wilson, E. M., Lubahn, D. B., Harding, A., & Fischbeck, K. (1991) · Nature · doi:10.1038/352077a0 · Cited by 2,801
Brook, J. D., McCurrach, M. E., Harley, H. G., Buckler, A., Church, D. M., Aburatani, H., Hunter, K. W., Stanton, V. P., Thirion, J., Hudson, T. J., et al. (1992) · Cell · doi:10.1016/0092-8674(92)90154-5 · Cited by 2,754
A polymorphic DNA marker genetically linked to Huntington's disease
Gusella, J. F., Wexler, N. S., Conneally, P. M., Naylor, S. L., Anderson, M. A., Tanzi, R. E., Watkins, P. C., Ottina, K. A., Wallace, M. R., Sakaguchi, A. Y., et al. (1983) · Nature · doi:10.1038/306234a0 · Cited by 2,340
Fu, Y.-H., Kuhl, D. P. A., Pizzuti, A., Pieretti, M., Sutcliffe, J. S., Richards, S., Verkert, A. J. M. H., Holden, J. J. A., Fenwick, R. G., Warren, S. T., et al. (1991) · Cell · doi:10.1016/0092-8674(91)90283-5 · Cited by 2,080
Myotonic Dystrophy Mutation: an Unstable CTG Repeat in the 3′ Untranslated region of the Gene
Mahadevan, M. S., Tsilfidis, C., Sabourin, L. A., Shutler, G., Amemiya, C. T., Jansen, G., Neville, C., Narang, M. A., Barceló, J. M., O'Hoy, K., et al. (1992) · Science · doi:10.1126/science.1546325 · Cited by 1,656
Absence of expression of the FMR-1 gene in fragile X syndrome
Pieretti, M., Zhang, F., Fu, Y.-H., Warren, S. T., Oostra, B. A., Caskey, C. T., & Nelson, D. L. (1991) · Cell · doi:10.1016/0092-8674(91)90125-i · Cited by 1,476
An Unstable Triplet Repeat in a Gene Related to Myotonic Muscular Dystrophy
Fu, Y., Pizzuti, A., Fenwick, R. G., King, J., Rajnarayan, S., Dunne, P. W., Dubel, J., Nasser, G. A., Ashizawa, T., de Jong, P., et al. (1992) · Science · doi:10.1126/science.1546326 · Cited by 1,453
Research works printed but not linked: 2
- Gusella, J. F., Varsanyi-Breiner, A., Kao, F. T.. Jones, C., Puck, T. T., Keys, C., Orkin, S., and Housman, D. E. (1979). Precise localiza- tion of the human @globin gene complex on chromosome 11. Proc. Natl. Acad. Sci. USA 76, 5239-5243.
- Lehrach, H., Drmanac, R.. Hoheisel, J., Larin, Z., Lennon, G., Nizetic, D., Monaco, A., Zehetner, G., and Poustka, A. (1990). Hybridisation fingerprinting in genome mapping and sequencing. In Genome Analy- sis: Genetic and Physical Mapping, Volume 1, K. E. Davies and S. M. Tighlman, eds. (Cold Spring Harbor, New York: Cold Spring Harbor Laboratory Press), pp. 39-81.
Cited by
Sorted by citations
Items 901–1,000 of 1,087
Alterations in synaptic function and plasticity in Huntington disease
Smith-Dijak, A., Sepers, M. D., & Raymond, L. A. (2019) · Journal of Neurochemistry · doi:10.1111/jnc.14723 · Cited by 158
Lazzaro, V. D., Bella, R., Benussi, A., Bologna, M., Borroni, B., Capone, F., Chen, K.-H. S., Chen, R. E., Chistyakov, A. V., Claßen, J., et al. (2021) · Clinical Neurophysiology · doi:10.1016/j.clinph.2021.05.035 · Cited by 163
The molecular and cellular basis of copper dysregulation and its relationship with human pathologies
Maung, M. T., Carlson, A., Olea‐Flores, M., Elkhadragy, L., Schachtschneider, K. M., Navarro‐Tito, N., & Padilla‐Benavides, T. (2021) · The FASEB Journal · doi:10.1096/fj.202100273rr · Cited by 158
Knock-in mouse models of Huntington’s disease
Menalled, L. (2005) · NeuroRx · doi:10.1602/neurorx.2.3.465 · Cited by 159
Richfield, E. K., Maguire‐Zeiss, K. A., Vonkeman, H. E., & Voorn, P. (1995) · Annals of Neurology · doi:10.1002/ana.410380605 · Cited by 153
Augood, S. J., Faull, R. L. M., Love, D. R., & Emson, P. C. (1996) · Neuroscience · doi:10.1016/0306-4522(95)00595-1 · Cited by 153
Protein precipitation: a common etiology in neurodegenerative disorders?
Kakizuka, A. (1998) · Trends in Genetics · doi:10.1016/s0168-9525(98)01559-5 · Cited by 152
Altered cholesterol and fatty acid metabolism in Huntington disease
Block, R. C., Dorsey, E. R., Beck, C. A., Brenna, J. T., & Shoulson, I. (2010) · Journal of Clinical Lipidology · doi:10.1016/j.jacl.2009.11.003 · Cited by 152
Taurine and central nervous system disorders
Menzie, J., Pan, C., Prentice, H. M., & Wu, J. (2012) · Amino Acids · doi:10.1007/s00726-012-1382-z · Cited by 153
Huntingtin Is Required for Normal Excitatory Synapse Development in Cortical and Striatal Circuits
McKinstry, S. U., Karadeniz, Y., Worthington, A. K., Hayrapetyan, V. Y., Ozlu, M. I., Serafin-Molina, K., Risher, W. C., Ustunkaya, T., Dragatsis, I., Zeitlin, S. O., et al. (2014) · Journal of Neuroscience · doi:10.1523/jneurosci.4699-13.2014 · Cited by 159
Siddiqui, A., Rivera, S., Castro, M. D. R., Acevedo‐Torres, K., Rane, A., Torres‐Ramos, C. A., Nicholls, D. G., Andersen, J. K., & Ayala‐Torres, S. (2012) · Free Radical Biology and Medicine · doi:10.1016/j.freeradbiomed.2012.06.008 · Cited by 154
Genome-wide loss of 5-hmC is a novel epigenetic feature of Huntington's disease
Wang, F., Yang, Y., Lin, X., Wang, J.-Q., Yong-sheng, W., Xie, W., Wang, D., Zhu, S., Liao, Y.-Q., Sun, Q., et al. (2013) · Human Molecular Genetics · doi:10.1093/hmg/ddt214 · Cited by 155
Bioactive Agents from Natural Sources: Trends in Discovery and Application
Grabley, S., & Thiericke, R. (1999) · Advances in biochemical engineering, biotechnology · doi:10.1007/3-540-49811-7_4 · Cited by 152
Tibben, A., Timman, R., Bannink, E. C., & Duivenvoorden, H. J. (1997) · Health Psychology · doi:10.1037//0278-6133.16.1.20 · Cited by 151
Retinal degeneration characterizes a spinocerebellar ataxia mapping to chromosome 3p
Gouw, L. G., Kaplan, C. D., Haines, J. H., Digre, K. B., Rutledge, S. L., Matilla‐Dueñas, A., Leppert, M., Zoghbi, H. Y., & Ptáček, L. J. (1995) · Nature Genetics · doi:10.1038/ng0595-89 · Cited by 152
Microglial activation in the pathogenesis of Huntington's disease
Yang, H.-M., Yang, S., Huang, S.-S., Tang, B.-S., & Guo, J.-F. (2017) · Frontiers in Aging Neuroscience · doi:10.3389/fnagi.2017.00193 · Cited by 151
Schilling, G., Coonfield, M. L., Ross, C. A., & Borchelt, D. R. (2001) · Neuroscience Letters · doi:10.1016/s0304-3940(01)02326-6 · Cited by 151
Reinstating Aberrant mTORC1 Activity in Huntington’s Disease Mice Improves Disease Phenotypes
Lee, J. H., Tecedor, L., Chen, Y. H., Mas, A., Sowada, M. J., Thompson, L. M., & Davidson, B. L. (2014) · Neuron · doi:10.1016/j.neuron.2014.12.019 · Cited by 151
Glucose Homeostasis in Huntington Disease
Lalic, N. M., Marić, J., Svetel, M. V., Jotić, A., Stefanova, E. D., Lalic, K. S., Dragašević, N., Milicic, T. J., Lukić, L., & Kostić, V. (2008) · Archives of Neurology · doi:10.1001/archneur.65.4.476 · Cited by 150
Plasma inflammatory biomarkers for Huntington’s disease patients and mouse model
Chang, K., Wu, Y., Chen, Y., & Chen, C. (2014) · Brain Behavior and Immunity · doi:10.1016/j.bbi.2014.09.011 · Cited by 152
Cerebral cortex structure in prodromal Huntington disease
Nopoulos, P., Aylward, E., Ross, C. A., Johnson, H. J., Magnotta, V. A., Juhl, A. R., Pierson, R. K., Mills, J. A., Langbehn, D. R., & Paulsen, J. S. (2010) · Neurobiology of Disease · doi:10.1016/j.nbd.2010.07.014 · Cited by 154
Hoss, A. G., Labadorf, A., Latourelle, J. C., Kartha, V. K., Hadzi, T. C., Gusella, J. F., MacDonald, M. E., Chen, J.-F., Akbarian, S., Weng, Z., et al. (2015) · BMC Medical Genomics · doi:10.1186/s12920-015-0083-3 · Cited by 151
Self-citationExplaining additional genetic variation in complex traits
Robinson, M. R., Wray, N. R., & Visscher, P. M. (2014) · Trends in Genetics · doi:10.1016/j.tig.2014.02.003 · Cited by 152
Huntington's disease: molecular basis of neurodegeneration
Rubinsztein, D. C., & Carmichael, J. (2003) · Expert Reviews in Molecular Medicine · doi:10.1017/s1462399403006549 · Cited by 155
FAN1 modifies Huntington’s disease progression by stabilizing the expanded HTT CAG repeat
Goold, R., Flower, M. D., Moss, D. J. H., Medway, C., Wood‐Kaczmar, A., André, R., Farshim, P. P., Bates, G. P., Holmans, P., Jones, L., et al. (2018) · Human Molecular Genetics · doi:10.1093/hmg/ddy375 · Cited by 150
Pao, P., & Tsai, L. (2021) · Journal of Biomedical Science · doi:10.1186/s12929-021-00774-y · Cited by 154
Mätlik, K., Baffuto, M., Kus, L., Deshmukh, A. L., Davis, D. A., Paul, M. R., Carroll, T. S., Caron, M., Masson, J., Pearson, C. E., et al. (2024) · Nature Genetics · doi:10.1038/s41588-024-01653-6 · Cited by 151
Rüb, U., Hoche, F., Brunt, E. R. P., Heinsen, H., Seidel, K., Turco, D. D., Paulson, H. L., Böhl, J., von Gall, C., Vonsattel, J., et al. (2012) · Brain Pathology · doi:10.1111/j.1750-3639.2012.00629.x · Cited by 150
Genetic modifiers of Huntington's disease
Gusella, J. F., MacDonald, M. E., & Lee, J. (2014) · Movement Disorders · doi:10.1002/mds.26001 · Cited by 150
Self-citationNeuronal palmitoyl acyl transferases exhibit distinct substrate specificity
Huang, K., Sanders, S. S., Singaraja, R. R., Orban, P. C., Cijsouw, T., Arstikaitis, P., Yanai, A., Hayden, M. R., & El-Husseini, A. (2009) · The FASEB Journal · doi:10.1096/fj.08-127399 · Cited by 150
Impacts of exercise interventions on different diseases and organ functions in mice
Guo, S., Huang, Y., Yan, Z., Huang, H., Hong, S., & Liu, T. (2019) · Journal of sport and health science/Journal of Sport and Health Science · doi:10.1016/j.jshs.2019.07.004 · Cited by 159
Khoshnan, A., Ko, J., & Patterson, P. H. (2002) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.022631799 · Cited by 151
Ishikawa, K., Tanaka, H., Saito, M., Ohkoshi, N., Fujita, T., Yoshizawa, K., Ikeuchi, T., Watanabe, M., Hayashi, A., Takiyama, Y., et al. (1997) · The American Journal of Human Genetics · doi:10.1086/514867 · Cited by 150
What have we learned from gene expression profiles in Huntington's disease?
Seredenina, T. S., & Luthi‐Carter, R. (2011) · Neurobiology of Disease · doi:10.1016/j.nbd.2011.07.001 · Cited by 145
Rodent genetic models of Huntington disease
Heng, M. Y., Detloff, P. J., & Albin, R. L. (2008) · Neurobiology of Disease · doi:10.1016/j.nbd.2008.06.005 · Cited by 152
A Genome Scan for Modifiers of Age at Onset in Huntington Disease: The HD MAPS Study
Li, J.-L., Hayden, M. R., Almqvist, E. W., Brinkman, R. R., Durr, A., Dodé, C., Morrison, P. J., Suchowersky, O., Ross, C. A., Margolis, R. L., et al. (2003) · The American Journal of Human Genetics · doi:10.1086/378133 · Cited by 126
Self-citationBiological and clinical manifestations of juvenile Huntington’s disease: A retrospective analysis
Fusilli, C., Migliore, S., Mazza, T., Consoli, F., De Luca, A., Barbagallo, G., Ciammola, A., Gatto, E. M., Cesarini, M., Etcheverry, J. L., et al. (2018) · The Lancet Neurology · doi:10.1016/s1474-4422(18)30294-1 · Cited by 148
Dangel, A. W., Mendoza, A. R., Menachery, C. D., Baker, B., Daniel, C., Carroll, M., Wu, L., & Yu, C. Y. (1994) · Immunogenetics · doi:10.1007/bf00177825 · Cited by 148
Resveratrol protects against peripheral deficits in a mouse model of Huntington's disease
Ho, D. J., Calingasan, N. Y., Wille, E. J., Dumont, M., & Beal, M. F. (2010) · Experimental Neurology · doi:10.1016/j.expneurol.2010.05.006 · Cited by 148
Proteins Containing Expanded Polyglutamine Tracts and Neurodegenerative Disease
Adegbuyiro, A., Sedighi, F., Pilkington, A. W., Groover, S. E., & Legleiter, J. A. (2017) · Biochemistry · doi:10.1021/acs.biochem.6b00936 · Cited by 144
Huntington’s Disease—Update on Treatments
Wyant, K. J., Ridder, A. J., & Dayalu, P. (2017) · Current Neurology and Neuroscience Reports · doi:10.1007/s11910-017-0739-9 · Cited by 154
The association of CAG repeat length with clinical progression in Huntington disease
Rosenblatt, A., Liang, K.-Y., Zhou, H., Abbott, M. H., Gourley, L. M., Margolis, R. L., Brandt, J., & Ross, C. A. (2006) · Neurology · doi:10.1212/01.wnl.0000204230.16619.d9 · Cited by 146
Influence of lamotrigine on progression of early Huntington disease
Kremer, B. P. H., Clark, C. M., Almqvist, E. W., Raymond, L. A., Graf, P., Jacova, C., Mezei, M., Hardy, M., Snow, B. J., Martin, W. R. W., et al. (1999) · Neurology · doi:10.1212/wnl.53.5.1000 · Cited by 147
Motor abnormalities in premanifest persons with Huntington's disease: The PREDICT‐HD study
Biglan, K., Ross, C. A., Langbehn, D. R., Aylward, E., Stout, J. C., Queller, S., Carlozzi, N. E., Duff, K., Beglinger, L. J., & Paulsen, J. S. (2009) · Movement Disorders · doi:10.1002/mds.22601 · Cited by 146
Plasma 24S-hydroxycholesterol and caudate MRI in pre-manifest and early Huntington's disease
Leoni, V., Mariotti, C., Tabrizi, S. J., Valenza, M., Wild, E. J., Henley, S. M. D., Hobbs, N. Z., Mandelli, M. L., Grisoli, M., Björkhem, I., et al. (2008) · Brain · doi:10.1093/brain/awn212 · Cited by 150
Rationale for intrastriatal grafting of striatal neuroblasts in patients with Huntington's disease
Peschanski, M., Césaro, P., & Hantraye, P. (1995) · Neuroscience · doi:10.1016/0306-4522(95)00162-c · Cited by 146
Effect of the myotonic dystrophy (DM) mutation on mRNA levels of the DM gene
Sabouri, L. A., Mahadevan, M. S., Narang, M. A., Lee, D. S. C., Surh, L. C., & Korneluk, R. G. (1993) · Nature Genetics · doi:10.1038/ng0793-233 · Cited by 146
Phosphorylation of profilin by ROCK1 regulates polyglutamine aggregation
Shao, J., Welch, W. J., DiProspero, N. A., & Diamond, M. I. (2008) · Molecular and Cellular Biology · doi:10.1128/mcb.00079-08 · Cited by 171
The Prevalence of Juvenile Huntington's Disease: A Review of the Literature and Meta-Analysis
Quarrell, O. W. J., O’Donovan, K., Bandmann, O., & Strong, M. (2012) · PLoS Currents · doi:10.1371/4f8606b742ef3 · Cited by 145
Simmons, D. A., Belichenko, N. P., Yang, T., Condon, C., Monbureau, M., Shamloo, M., Jing, D., Massa, S. M., & Longo, F. M. (2013) · Journal of Neuroscience · doi:10.1523/jneurosci.1310-13.2013 · Cited by 145
Villar-Menéndez, I., Blanch, M., Tyebji, S., Pereira‐Veiga, T., Albasanz, J. L., Martı́n, M., Ferrer, I., Pérez‐Navarro, E., & Barrachina, M. (2013) · NeuroMolecular Medicine · doi:10.1007/s12017-013-8219-0 · Cited by 144
Wu, J., Shih, H.-P., Vigont, V. A., Hrdlicka, L., Diggins, L. T., Singh, C. M., Mahoney, M. B., Chesworth, R., Shapiro, G., Zimina, O. A., et al. (2011) · Chemistry & Biology · doi:10.1016/j.chembiol.2011.04.012 · Cited by 143
Ratovitski, T., Guček, M., Jiang, H., Chighladze, E., Waldron, E., D'Ambola, J., Hou, Z., Liang, Y., Poirier, M. A., Hirschhorn, R. R., et al. (2009) · Journal of Biological Chemistry · doi:10.1074/jbc.m804813200 · Cited by 144
Southwell, A. L., Skotte, N. H., Kordasiewicz, H. B., Østergaard, M. E., Watt, A. T., Carroll, J. B., Doty, C. N., Villanueva, E. B., Petoukhov, E., Vaid, K., et al. (2014) · Molecular Therapy · doi:10.1038/mt.2014.153 · Cited by 150
Lipid rafts: Keys to neurodegeneration
Schengrund, C. (2010) · Brain Research Bulletin · doi:10.1016/j.brainresbull.2010.02.013 · Cited by 146
Ciurea, A. V., Mohan, A. G., Covache-Busuioc, R.-A., Costin, H. P., Glavan, L.-A., Corlatescu, A.-D., & Saceleanu, V. M. (2023) · International Journal of Molecular Sciences · doi:10.3390/ijms241310809 · Cited by 150
Mittoux, V., Joseph, J., Condé, F., Palfi, S., Dautry, C., Poyot, T., Bloch, J., Déglon, N., Ouary, S., Nimchinsky, E. A., et al. (2000) · Human Gene Therapy · doi:10.1089/10430340050015220 · Cited by 145
Earliest functional declines in Huntington disease
Beglinger, L. J., O’Rourke, J. J. F., Wang, C., Langbehn, D. R., Duff, K., & Paulsen, J. S. (2010) · Psychiatry Research · doi:10.1016/j.psychres.2010.04.030 · Cited by 147
Programmed cell death: Implications for neuropsychiatric disorders
Margolis, R. L., Chuang, D., & Post, R. M. (1994) · Biological Psychiatry · doi:10.1016/0006-3223(94)91241-6 · Cited by 143
Role of oxidative DNA damage in mitochondrial dysfunction and Huntington’s disease pathogenesis
Ayala‐Peña, S. (2013) · Free Radical Biology and Medicine · doi:10.1016/j.freeradbiomed.2013.04.017 · Cited by 147
Mutant huntingtin fragmentation in immune cells tracks Huntington’s disease progression
Weiss, A., Träger, U., Wild, E. J., Grueninger, S., Farmer, R. E., Landles, C., Scahill, R. I., Lahiri, N., Salman, H., Macdonald, D., et al. (2012) · Journal of Clinical Investigation · doi:10.1172/jci64565 · Cited by 141
Quantitative Susceptibility Mapping Suggests Altered Brain Iron in Premanifest Huntington Disease
Bergen, J. M. G. V., Hua, J., Unschuld, P. G., Lim, I. A. L., Jones, C. K., Margolis, R. L., Ross, C. A., van Zijl, P. C. M., & Li, X. (2015) · American Journal of Neuroradiology · doi:10.3174/ajnr.a4617 · Cited by 140
Current Pharmacological Approaches to Reduce Chorea in Huntington’s Disease
Coppen, E. M., & Roos, R. A. C. (2016) · Drugs · doi:10.1007/s40265-016-0670-4 · Cited by 152
† (2014) · The Lancet Neurology · doi:10.1016/s1474-4422(14)70262-5 · Cited by 144
Sermon, K., Goossens, V., Seneca, S., Lissens, W., Vos, A. D., Vandervorst, M., Steirteghem, A. V., & Liebaers, I. (1998) · Prenatal Diagnosis · doi:10.1002/(sici)1097-0223(199812)18:13 · Cited by 143
Mechanisms of Disease: histone modifications in Huntington's disease
Sadri‐Vakili, G., & Cha, J.-H. J. (2006) · Nature Clinical Practice Neurology · doi:10.1038/ncpneuro0199 · Cited by 143
Björkqvist, M., Fex, M., Renström, E., Wierup, N., Petersén, Å., Gil‐Mohapel, J., Bacos, K., Popović, N., Li, J., Sundler, F., et al. (2005) · Human Molecular Genetics · doi:10.1093/hmg/ddi053 · Cited by 143
Differential Electrophysiological Changes in Striatal Output Neurons in Huntington's Disease
André, V. M., Cepeda, C., Fisher, Y. E., Huynh, M. N., Bardakjian, N., Singh, S., Yang, X. W., & Levine, M. S. (2011) · Journal of Neuroscience · doi:10.1523/jneurosci.3539-10.2011 · Cited by 138
Choe, C.-U., & Ehrlich, B. E. (2006) · Science s STKE · doi:10.1126/stke.3632006re15 · Cited by 142
The Clinical and Genetic Features of Huntington Disease
Sturrock, A., & Leavitt, B. R. (2010) · Journal of Geriatric Psychiatry and Neurology · doi:10.1177/0891988710383573 · Cited by 144
Zinzi, P., Salmaso, D., Grandis, R. D., Graziani, G., Maceroni, S., Bentivoglio, A. R., Zappata, P., Frontali, M., & Jacopini, G. (2007) · Clinical Rehabilitation · doi:10.1177/0269215507075495 · Cited by 150
Mutant huntingtin impairs Ku70-mediated DNA repair
Enokido, Y., Tamura, T., Ito, H., Arumughan, A., Komuro, A., Shiwaku, H., Sone, M., Foulle, R., Sawada, H., Ishiguro, H., et al. (2010) · The Journal of Cell Biology · doi:10.1083/jcb.200905138 · Cited by 144
Yin, X., Mańczak, M., & Reddy, P. H. (2016) · Human Molecular Genetics · doi:10.1093/hmg/ddw045 · Cited by 144
Fautsch, M. P., Wieben, E. D., Baratz, K. H., Bhattacharyya, N., Sadan, A. N., Hafford‐Tear, N. J., Tuft, S. J., & Davidson, A. E. (2020) · Progress in Retinal and Eye Research · doi:10.1016/j.preteyeres.2020.100883 · Cited by 148
Fast transport and retrograde movement of huntingtin and HAP 1 in axons
Block-Galarza, J., Chase, K. O., Sapp, E., Vaughn, K. T., Vallee, R. B., DiFiglia, M., & D, N. A. M. (1997) · Neuroreport · doi:10.1097/00001756-199707070-00031 · Cited by 142
Polyglutamines Placed into Context
Spada, A. R. L., & Taylor, J. P. (2003) · Neuron · doi:10.1016/s0896-6273(03)00328-3 · Cited by 142
Rubinsztein, D. C., Amos, W., Leggo, J., Goodburn, S. F., Ramesar, R., Old, J., Bontrop, R. E., McMahon, R., Barton, D. E., & Ferguson-Smith, M. A. (1994) · Nature Genetics · doi:10.1038/ng0894-525 · Cited by 142
Mutant Huntingtin Expression Induces Mitochondrial Calcium Handling Defects in Clonal Striatal Cells
Milakovic, T., Quintanilla, R. A., & Johnson, G. V. W. (2006) · Journal of Biological Chemistry · doi:10.1074/jbc.m603845200 · Cited by 142
Reduced Penetrance of the Huntington's Disease Mutation
McNeil, S. M., Novelletto, A., Srinidhi, J., Barnes, G., Kornbluth, I., Altherr, M. R., Wasmuth, J. J., Gusella, J. F., MacDonald, M. E., & Myers, R. H. (1997) · Human Molecular Genetics · doi:10.1093/hmg/6.5.775 · Cited by 142
Self-citationHarris, G. J., Codori, A. M., Lewis, R. F., Schmidt, E. U., Bedi, A., & Brandt, J. (1999) · Brain · doi:10.1093/brain/122.9.1667 · Cited by 139
Regulation of neural circuit formation by protocadherins
Peek, S. L., Mah, K. M., & Weiner, J. A. (2017) · Cellular and Molecular Life Sciences · doi:10.1007/s00018-017-2572-3 · Cited by 119
Inhibition of Metabotropic Glutamate Receptor Signaling by the Huntingtin-binding Protein Optineurin
Anborgh, P. H., Godin, C. M., Pampillo, M., Dhami, G. K., Dale, L. B., Cregan, S. P., Truant, R., & Ferguson, S. S. G. (2005) · Journal of Biological Chemistry · doi:10.1074/jbc.m504508200 · Cited by 141
The CB1 cannabinoid receptor signals striatal neuroprotection via a PI3K/Akt/mTORC1/BDNF pathway
Blázquez, C., Chiarlone, A., Bellocchio, L., Resel, E., Pruunsild, P., García-Rincón, D., Sendtner, M., Timmusk, T., Lutz, B., Galve‐Roperh, I., et al. (2015) · Cell Death and Differentiation · doi:10.1038/cdd.2015.11 · Cited by 143
Young, F. B. J., Butland, S. L., Sanders, S. S., Sutton, L. M., & Hayden, M. R. (2011) · Progress in Neurobiology · doi:10.1016/j.pneurobio.2011.11.002 · Cited by 143
Chiu, C., Liu, G., Leeds, P. R., & Chuang, D. (2011) · Neuropsychopharmacology · doi:10.1038/npp.2011.128 · Cited by 146
Redox Mechanisms in Neurodegeneration: From Disease Outcomes to Therapeutic Opportunities
Sbodio, J. I., Snyder, S. H., & Paul, B. D. (2018) · Antioxidants and Redox Signaling · doi:10.1089/ars.2017.7321 · Cited by 149
Suppression of Huntington's disease pathology in Drosophila by human single-chain Fv antibodies
Wolfgang, W. J., Miller, T. W., Webster, J. M., Huston, J. S., Thompson, L. M., Marsh, J., & Messer, A. C. (2005) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0505321102 · Cited by 146
Reduced expression of the TrkB receptor in Huntington's disease mouse models and in human brain
Ginés, S., Bosch, M., Marco, S., Gavaldà, N., Dı́az-Hernández, M., Lucas, J. J., Canals, J. M., & Alberch, J. (2006) · European Journal of Neuroscience · doi:10.1111/j.1460-9568.2006.04590.x · Cited by 141
Caspases and neurodegeneration: on the cutting edge of new therapeutic approaches
Wellington, C. L., & Hayden, M. R. (2000) · Clinical Genetics · doi:10.1034/j.1399-0004.2000.570101.x · Cited by 141
DNA analysis in hereditary dentatorubral-pallidoluysian atrophy
Komure, O., Sano, A., Nishino, N., Yamauchi, N., Ueno, S., Kondoh, K., Sano, N., Takahashi, M., Murayama, N., Kondo, I., et al. (1995) · Neurology · doi:10.1212/wnl.45.1.143 · Cited by 141
Quinti, L., Dayalan Naidu, S., Träger, U., Chen, X., Kegel-Gleason, K., Llères, D., Connolly, C., Chopra, V., Low, C., Moniot, S., et al. (2017) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1614943114 · Cited by 140
Trinucleotide repeats in human genome and exome
Kozłowski, P., de Mezer, M., & Krzyżosiak, W. J. (2010) · Nucleic Acids Research · doi:10.1093/nar/gkq127 · Cited by 140
Gwinn, K. A. (2002) · Movement Disorders · doi:10.1002/mds.10173 · Cited by 139
Oliveira, J. M. A., Chen, S., Almeida, S., Riley, R. R., Gonçalves, J., Oliveira, C. R., Hayden, M. R., Nicholls, D. G., Ellerby, L., & Rego, A. C. (2006) · Journal of Neuroscience · doi:10.1523/jneurosci.3004-06.2006 · Cited by 145
Chan, J. C. C., Oyler, N. A., Yau, W., & Tycko, R. (2005) · Biochemistry · doi:10.1021/bi050724t · Cited by 141
Meltzer, S. J., Yin, J., Manin, B., Rhyu, M. G., Cottrell, J. R., Hudson, E., Redd, J. L., Krasna, M. J., Abraham, J. M., & Reid, B. J. (1994) · PubMed · Cited by 140
Brain-Derived Neurotrophic Factor in Patients with Huntington's Disease
Zuccato, C., Marullo, M., Vitali, B., Tarditi, A., Mariotti, C., Valenza, M., Lahiri, N., Wild, E. J., Sassone, J., Ciammola, A., et al. (2011) · PLoS ONE · doi:10.1371/journal.pone.0022966 · Cited by 138
Huntington’s disease: Clinical presentation and treatment
Novak, M. J. U., & Tabrizi, S. J. (2011) · International Review of Neurobiology · doi:10.1016/b978-0-12-381328-2.00013-4 · Cited by 137
The role of tau in the pathological process and clinical expression of Huntington’s disease
Vuono, R., Winder‐Rhodes, S., de Silva, R., Cisbani, G., Drouin‐Ouellet, J., REGISTRY Investigators of the European Huntington’s Disease Network, Spillantini, M. G., Cicchetti, F., & Barker, R. A. (2015) · Brain · doi:10.1093/brain/awv107 · Cited by 139
Decreased cAMP Response Element-mediated Transcription
Sugars, K. L., Brown, R. L., Cook, L. J., Swartz, J., & Rubinsztein, D. C. (2004) · Journal of Biological Chemistry · doi:10.1074/jbc.m310226200 · Cited by 139
Metadata
- Authors
- MACDONALD, M.
- Affiliations
- Harvard University (US)
- Corresponding author
- MACDONALD, M
- Venue
- Cell
- Publisher
- Elsevier BV
- Published
- 1993-03
- Volume
- 72
- Issue
- 6
- Pages
- 971-983
- ISSN
- 0092-8674 (ISSN-L)
- OpenAlex
- W2121642311
- Semantic Scholar
- 47661acc507387c5d4de447493481bb376f88728
- Cited by
- 8,366
- References
- 60
- Citations by year
- 2026: 181 · 2025: 272 · 2024: 303 · 2023: 271 · 2022: 293 · 2021: 361 · 2020: 310 · 2019: 275 · 2018: 341 · 2017: 287 · 2016: 329 · 2015: 290 · 2014: 323 · 2013: 328 · 2012: 313
- FWCI
- 77.80
- Type
- journal article
- Language
- en
- Open access
- bronze
- doi.org
- Locations
- Cell (publishedVersion)
- PubMed (publishedVersion)
- CaltechAUTHORS (California Institute of Technology) (submittedVersion)
- Deep Blue (University of Michigan) (submittedVersion)
- ORCA Online Research @Cardiff (Cardiff University) (submittedVersion)
- Funders
- W. M. Keck Foundation
- Dana Foundation
- Hereditary Disease Foundation
- Bristol-Myers Squibb
- Wellcome Trust
- National Institutes of Health (5r01ns025631-06)
- Medical Research Council
- National Institute of Neurological Disorders and Stroke (R01NS022031, NS25631, NS 16367, NS22031)
- Topics
- Life Sciences › Neuroscience › Cellular and Molecular Neuroscience › Genetic Neurodegenerative Diseases
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Genetics › Genetics and Neurodevelopmental Disorders
- Health Sciences › Medicine › Pathology and Forensic Medicine › Genetic factors in colorectal cancer
- Keywords
- Huntington's disease, trinucleotide repeat expansion, CAG repeat, IT15 gene, chromosome 4p16.3, haplotype analysis, linkage disequilibrium, repeat instability, fragile X syndrome, myotonic dystrophy, gene mapping
- MeSH terms
- Amino Acid Sequence, Base Sequence, Chromosomes, Human, Pair 4, Cloning, Molecular, Exons, Genes, Humans, Huntington Disease, Molecular Sequence Data, Mutation, Oligodeoxyribonucleotides, Pedigree, Polymorphism, Genetic, Repetitive Sequences, Nucleic Acid, RNA, Messenger, Restriction Mapping, Gene Expression, Polymerase Chain Reaction
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
